The Affiliated Hospital of Inner Mongolia Medical University
Beijing Yi Hua Hospital Management Co., Ltd
The Second Hospital of Hebei Medical University
The First Affiliated Hospital of Shanxi Medical University
Shaanxi Provincial People's Hospital
Jining Medical University
Qingdao Municipal Hospital
Daqing Oil Field Hospital
First Affiliated Hospital of Jinan University
Meizhou People's Hospital
Meiheko Central Hospital
A total of 270 Chinese mild to moderate Asthma patients will be enrolled and 230 will be completed in this multi-center, randomized, single blind, parallel efficacy and safety comparison study of budesonide HFA MDI 200 mcg 2 puffs BID versus budesonide DPI (Turbuhaler) 100 mcg 4 puffs BID.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged 18 to 70 years old and diagnosed as Asthma in clinics
Diagnosed as Asthma according to the 2016 Asthma guidance of Chinese Thoracic Society, and without administer corticosteroids within three months, either new or old patients
FEV1 predicted ≧ 60%
Patients is willing to participate the study and signed the Informed Consent Form
You may not be if
Allergy to budesonide or salbutamol
Infections of Respiratory tract, nasal-sinus and ear within 4 weeks before enrollment
Severe nasal allergy and need the treatment of corticostreoids and histamines.
Severe cardiovascular disease history
Has used leukotriene receptor antagonist (Montelukast, Pranlukast, Zafirlukast etc.) within 2 weeks before enrollment
Severe cognition or mental disorder and can not cooperation with the treatment
Significant liver dysfunction, AST, ALT \> 3 X normal upper limits, CR \> 1.5 X normal upper limits
Patients with uncontrolled diabetes or fasting blood glucose \> 10 mmol/L
Patients currently receiving beta-antagonists or beta-agonists treatment (including eye drops)
Patients who has contraindications to beta2-agonists
Patients who has participated others drug's clinical study within three months
Female patients who are pregnant or lactation or prepare to pregnant
Any conditions which the investigators considered not suitable to enrolled
Clareo Health | Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients
